| ¿µ¹® | hepatitis | ÇÑ±Û | °£¿° |
|---|---|---|---|
| ¼³¸í | °£¿¡ »ý±â´Â ¿°ÁõÀ» ÅëÆ²¾î À̸£´Â ¸». ¹ß¿-Ȳ´Þ-Àü½Å±ÇÅÂ-¼ÒÈ Àå¾ÖÀÇ Áõ»óÀ» º¸À̴µ¥, ÁÖµÈ ¿øÀÎÀº À½½Ä¹°°ú Ç÷¾×À» ÅëÇÑ ¹ÙÀÌ·¯½º °¨¿°ÀÌ¸ç ±× ¹Û¿¡ ¾à¹°, ¾ËÄÚ¿Ã, ¾Ë·¹¸£±â µîÀÌ ¿øÀÎÀÎ °Íµµ ÀÖ´Ù. ÀÌ °£¿°Àº ±× Áö¼Ó±â°£¿¡ µû¶ó¼ ±Þ¼º°£¿°°ú ¸¸¼º°£¿°À¸·Î ³ª´©´Âµ¥, ¸¸¼º°£¿°Àº 6°³¿ù ÀÌ»ó °£¿°ÀÌ Áö¼ÓµÇ´Â °æ¿ì¸¦ ¸»ÇÏ°í ±Þ¼º°£¿°Àº 6°³¿ù ÀÌ»ó Áö¼ÓÇÏÁö ¸øÇÏ´Â °æ¿ì¸¦ ¸»ÇÑ´Ù. ±Þ¼º°£¿°Àº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼, °£ÀÇ ±Þ¼º-½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀÌ´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༱°£¿°(AÇü)°ú Ç÷û°£¿°(BÇü)ÀÇ µÎ Á¾·ù°¡ Àִµ¥, À̵éÀº ¸ðµÎ Àü¿°¼º ÁúȯÀÌÁö¸¸ °¨¿° °æ·Î´Â ´Ù¸£´Ù. °¨¿° °æ·Î·Î À¯Ç༱°£¿°¹ÙÀÌ·¯½º´Â Ç÷¾×-»ùâÀÚ¾×-´ëº¯ Áß¿¡¼ Áõ¸íµÇ¹Ç·Î Àü¿°µÈ ¹°-À½½ÄÀ» ÅëÇÏ¿© °æ±¸°¨¿°µÇ°Å³ª ȯÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃË¿¡ ÀÇÇØ¼ °¨¿°µÈ´Ù. Ç÷û°£¿°Àº ¿À·ÎÁö ºñ°æ±¸Àû °¨¿°À¸·Î ȯÀÚÀÇ Ç÷û, Ç÷¾×ÀÇ ÁÖ»ç, ȯÀÚÀÇ Ç÷¾×¿¡ °¨¿°µÈ ÁÖ»ç±â µîÀ¸·Î °¨¿°µÈ´Ù. Àẹ±â´Â À¯Ç༺°£¿°ÀÌ 2~6ÁÖ°£À̰í, Ç÷û °£¿°Àº 6ÁÖ~6°³¿ù °¡·® µÈ´Ù. Ç÷û°£¿°Àº À¯ÇàÀÇ °èÀý-¿¬·É°ú´Â °ü°è°¡ ¾øÀ¸³ª, À¯Ç༺°£¿°Àº ÁÖ·Î °¡À»¿¡¼ °Ü¿ï¿¡ °ÉÃÄ ¸¹°í û¼Ò³â¿¡ ¸¹´Ù. Áõ¼¼´Â ¹ßº´Çϱâ 1ÁÖÀÏ ÀüºÎÅÍ ¿Â¸öÀÌ ³ë°ïÇÏ°í ½Ä¿åÀÌ ¶³¾îÁö¸ç µÎÅëÀÌ ÀÖ°í »óº¹ºÎ¿¡ ºÒÄè°¨ÀÌ »ý±â´Âµ¥, À¯Ç༺°£¿°¿¡¼´Â Ȳ´ÞÀÌ ³ªÅ¸³ª±â Àü¿¡ ¹ß¿(38¡É ÀüÈÄ)ÀÌ ÀÖÀ» ¶§°¡ ¸¹°í ¼öÀÏ ÈÄ¿¡ ÇØ¿µÈ´Ù. ¶Ç, °üÀý-Ç㸮°¡ ¾ÆÇà ¶§µµ ÀÖ¾î óÀ½¿¡´Â °¨±â·Î ¿ÀÀÎÇÒ ¶§°¡ ¸¹´Ù. Ç÷û°£¿°Àº ÀÌ·¯ÇÑ Ãʱâ Áõ¼¼°¡ °¡º±°í ¼¼È÷ ¹ßº´ÇÏ´Â °ÍÀÌ ¸¹´Ù. ÁÖÁõ¼¼´Â À§ÀåÁõ¼¼¿Í Ȳ´ÞÀ̸ç, ½Ä¿åºÎÁø-±¸Åä-±¸¿ªÁú, »óº¹ºÎÀÇ µÐÅë µîÀÌ ÀϾ¸ç, ¹ßº´ ÈÄ 4~5ÀÏ¿¡ Ȳ´ÞÀÌ ³ªÅ¸³´Ù. Ȳ´ÞÀº 1ÁÖÀÏÀ» ÀüÈÄÇÏ¿© ÃÖ°í¿¡ À̸£¸ç, ±× ÈÄ 1°³¿ù »çÀÌ¿¡ ¾ø¾îÁö¸é¼ ´Ù¸¥ Áõ¼¼µµ ÁÁ¾ÆÁø´Ù. °æ°ú´Â ±Þ¼º°£¿°Àº ¾à 70%°¡ ´ë°³ 1~3°³¿ù À̳»¿¡ Ä¡À¯µÇÁö¸¸ »¡¸® Ä¡·áµÇÁö ¾Ê´Â °Í Áß 15%°¡ ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϸç, ±× ÀϺδ °£°æÈÁõÀ¸·Î ÀÌÇàÇÑ´Ù. ±Þ¼º°£¿° Áß¿¡´Â ¶§·Î´Â 10ÀÏ À̳»¿¡ »ç¸ÁÇÏ´Â Àü°Ý¼º°£¿°À̶ó°í ÇÏ´Â °Íµµ ÀÖ´Ù. º´ÀÇ Àüü °æ°ú Áß È²´ÞÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¹«È²´Þ¼º °£¿°À̶ó°í ÇÏ´Â °Íµµ ÀÖ¾î. ¸¸¼º°£¿°À¸·Î ÀÌÇàÇÏ´Â °Í¿¡´Â ÀÌ ¹«È²´Þ¼ºÀÌ ¸¹Àº °æÇâÀÌ ÀÖ´Ù. Ç÷û°£¿°µµ ¸¸¼ºÈÇϱ⠽±´Ù. |
||
| ¿µ¹® | acute hepatitis | ÇÑ±Û | ±Þ¼º°£¿° |
|---|---|---|---|
| ¼³¸í | ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, ÀÌ´Â ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇÏ´Â ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇÏ´Â À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°ÀÌ¸ç ³ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇÏ´Â À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀÌ Ã£¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³´Ù. µÚÀ̾î Ȳ´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª Ȳ´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â Ȳ´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» ÇØµµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀÌ Æ¯Â¡ÀÌ¸ç ±Þ¼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º¿î °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀÎ °ÍÀÌ º¸ÅëÀÌ´Ù. |
||
| ¿µ¹® | chronic active hepatitis | ÇÑ±Û | ¸¸¼ºÈ°µ¿°£¿° |
|---|---|---|---|
| ¼³¸í | BÇü °£¿°À̳ª ºñAÇü£ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Ư¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀÇ Ä§À±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ Ȳ´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈÁõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù. |
||
| ¿µ¹® | fulminant hepatitis | ÇÑ±Û | Àü°Ý°£¿° |
|---|---|---|---|
| ¼³¸í | ¹ÙÀÌ·¯½º °£¿°ÀÇ ÇÑ ÇüÀ¸·Î ±Þ¼º Ȳ»öÀ§ÃàÁõÀ̶ó°íµµ ºÎ¸¥´Ù. °£¼¼Æ÷ÀÇ ´ëºÎºÐÀÌ ±«»ç»óÅ·ΠµÇ¸ç ȯÀÚ´Â º¸Åë »ç¸ÁÇÑ´Ù. Ȳ´ÞÀÌ ³ªÅ¸³ª±â ÀüºÎÅÍ ÀÌ¹Ì Áõ»óÀº ÇöÀúÈ÷ ÁøÇàÇÏ¿© Ȳ´ÞÀÇ ÃâÇöµµ ºü¸£°í, ±Þ¼º ¹ß¿À» ¼ö¹ÝÇϸç Á¡¸·À̳ª ÇÇÇÏÃâÇ÷À» º¼ ¼ö ÀÖ´Ù. °£ÀÇ ¾ÐÅëÀ» ¼ö¹ÝÇÏ´Â ¼öµµ ÀÖ´Ù. À§Ãà¿¡ ÀÇÇÏ¿© °£Àº ÀÚÁÖ ÀÛ¾ÆÁø´Ù. ÃÖÈÄ¿¡´Â ÀǽÄÀå¾Ö¸¦ ÃÊ·¡ÇÏ¿© Á¹À½ÀÌ ¿À°í È¥¹Ì»óÅ·ΠµÇ¸ç °£¼ºÈ¥¼ö·Î ÁøÇàÇÏ¿© »ç¸ÁÇÏ°Ô µÈ´Ù. Áõ»óÀÌ ½ÃÀ۵Ǿî 2~3ÁÖ ³»¿¡ °£³úº´Áõ±îÁö ÁøÇàÇÏ´Â °£±â´É »ó½ÇÀ» Àü°Ý¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸£¸ç, ÁøÇà ¼Óµµ°¡ ºü¸£Áö ¾Ê¾Æ¼ 3°³¿ù¿¡ À̸£·¯ °£±â´É»ó½Ç¿¡ ºüÁö´Â °ÍÀº ¾Æ±Þ¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸¥´Ù. ¸ðµç °£¿° ¹ÙÀÌ·¯½º°¡ ¸ðµÎ ÀÏÀ¸Å°Áö´Â ¾Ê´Â´Ù. °£¿°A¹ÙÀÌ·¯½º¿Í °£¿°E¹ÙÀÌ·¯½º´Â º¸À¯ÀÚ »óųª ¸¸¼º °£¿°À» °ÅÀÇ ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. ±âŸ ´Ù¸¥ °¨¿° ¶Ç´Â ºñ°¨¿°¼º ¿øÀÎ, ƯÈ÷ ¾à¹°°ú µ¶¼Òµµ º»ÁúÀûÀ¸·Î µ¿ÀÏÇÑ ÁõÈĸ¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ±×·¯¹Ç·Î ¹ÙÀÌ·¯½º¼º °£¿°ÀÇ Áø´Ü°ú °¢ °£¿° ¹ÙÀÌ·¯½º¸¦ ±¸º°Çϴµ¥´Â Ç÷ûÇÐÀû °Ë»ç°¡ ÇʼöÀûÀÌ´Ù. |
||
| AH | abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro... |
|---|---|
| CAH | chronic active hepatitis; chronic aggressive hepatitis; combined atrial hypertrophy; congenital adre... |
| HA | H antigen; Hakim-Adams [syndrome]; halothane anesthesia; Hartley [guinea pig]; headache; health alli... |
| HBV | hepatitis B vaccine; hepatitis B virus |
| HDV | hepatitis D virus; hepatitis delta virus |
| AIH | 1)autoimmune hepatitis |
|---|---|
| AAH | Acute alcoholic hepatitis |
| AH | Acute hepatitis |
| AH | Alcoholic hepatitis |
| HAV | Anti-Hepatitis A virus |
| acute parenchymatous hepatitis | A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice. Synonym: acute parenchymatous hepatitis, Rokitansky's disease. (05 Mar 2000) |
|---|---|
| anicteric hepatitis | Hepatitis without jaundice. (05 Mar 2000) |
| anicteric virus hepatitis | A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis. (05 Mar 2000) |
| autoimmune hepatitis | <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver. Symptoms are those of chronic active hepatitis. (27 Sep 1997) |
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
| vaccination, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| vaccination, infectious hepatitis | See Vaccination, hepatitis a. (12 Dec 1998) |
| vaccineation, serum hepatitis | See Vaccination, hepatitis b. (12 Dec 1998) |
| giant cell hepatitis | Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop. Synonym: giant cell hepatitis. (05 Mar 2000) |
| viral hepatitis | Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver. (12 Dec 1998) |
| viral hepatitis type A | A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom. Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis. (05 Mar 2000) |
| viral hepatitis type B | A virus disease with a long incubation period (usually 50 to 160 days), caused by hepatitis B virus, a DNA virus and member of the family Hepadnoviridae, usually transmitted by injection of infected blood or blood derivatives or by use of contaminated needles, lancets, or other instruments; clinically and pathologically similar to viral hepatitis type A, but there is no cross-protective immunity; HBsAg is found in the serum and the hepatitis delta virus occurs in some patients. Synonym: hepatitis B, serum hepatitis, transfusion hepatitis, virus B hepatitis. (05 Mar 2000) |
| viral hepatitis type C | Principal cause of non-A, non-B posttransfusion hepatitis caused by an RNA virus that may be related to Flaviviridae family. Synonym: hepatitis C, virus C hepatitis. (05 Mar 2000) |
| viral hepatitis type D | Acute or chronic hepatitis caused by the hepatitis delta virus, a defective RNA virus requiring HBV for replication. The acute type occurs in two forms: 1) coinfection, the simultaneous occurrence of hepatitis B virus and hepatitis delta virus infections, which usually is self-limiting; 2) superinfection, the appearance of hepatitis delta virus infection in a hepatitis B virus carrier, which often leads to chronic hepatitis The chronic type appears to be more severe than other types of viral hepatitis. Synonym: delta hepatitis, hepatitis D. (05 Mar 2000) |
| viral hepatitis type E | Hepatitis caused by a nonenveloped, single-stranded, positive-sense RNA virus 27-34 nm in diameter, unrelated to other hepatitis; it is the principal cause of enterically transmitted, waterborne, epidemic NANB hepatitis occurring primarily in Asia and Africa. Synonym: hepatitis E. (05 Mar 2000) |
| hepatitis G virus |
(HGV) a parenterally transmitted flavivirus originally isolated from a patient with chronic hepatitis and considered to be identical to hepatitis GB virus-C; most infections are benign, and the role of HGV in the etiology of liver disease is uncertain.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
|
|---|---|
| hepatitis G |
A viral hepatitis described in 1996. The nature and significance of this viral hepatitis is still under investigation
Ãâó: www.gastrolab.net/dicteh.htm
|
| hepatitis G |
A newly identified strain of hepatitis, hepatitis G is currently under study. The first major study of virus has reported that those infected by means other than blood transfusions did not develop chronic liver disease, although for most the virus remained in their blood for several years. It is not clear at this time how widespread hepatitis G is, what the means of transmission are, or what its precise effects are on infected patients.
Ãâó: www.epidemic.org/glossaryText/glossaryH.html
|
| hepatitis G |
The hepatitis G virus (also called hepatitis GB virus or HGBV-C) is a distant relative of the hepatitis C virus. It appears to be transmitted through transfusions (one to two percent of US blood donors have HGV RNA detectable in their serum). Its role in acute and chronic hepatitis remains unclear. Recent studies suggest that the virus may not even replicate in the liver. At the present time, HGV does not appear to be an important cause of clinical liver disease. ...
Ãâó: www.hepb.org/hepb/glossary.htm
|
| hepatitis G v. |
a parenterally transmitted flavivirus originally isolated from a patient with chronic hepatitis and considered to be identical to hepatitis GB virus-C; most infections are benign, and the role of HGV in the etiology of liver disease is uncertain.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|